OrthoPediatrics Corp.
NASDAQ:KIDSMedical - Devices
+$0.19 today
- Market cap
- $826.40M
- Beta
- 1.01
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$1.68
Volume 0.16M
Average 0.16M
KIDS Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
OrthoPediatrics Corp.NASDAQ: KIDS
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin holds steady near 73.1%
Gross margin was 73.1% in Q1 FY2026, up 0.1 pp from a year earlier. On a trailing-twelve-month basis it was 73.1%, up 0.3 pp year over year. Over 3 fiscal years it narrowed by 1.1 pp.
Context
- Gross margin widened in 2 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 73.1%
- Year-over-year change
- +0.5pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 73.1% | +0.5pp |
| FY2024 | 2024-12-31 | 72.6% | -2.2pp |
| FY2023 | 2023-12-31 | 74.8% | +0.7pp |
| FY2022 | 2022-12-31 | 74.1% | -0.7pp |
| FY2021 | 2021-12-31 | 74.9% | — |
Gross Margin vs competitors
How KIDS compares with its peers on the latest reported figures
- KIDS's LTM Mar 2026 gross margin of 73.1% is the 4th highest of the 8 companies compared; the peer median is 67.8%.
- Its year-over-year change of +0.3 pp is the 4th highest of 8, against a peer median of +0.1 pp.
- Over three fiscal years its change of -1.1 pp compares with a peer median of +4.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
CBLLCeriBell, Inc. | LTM Mar 2026 | 87.7% | +0.5 pp | +5.0 pp |
| LTM Mar 2026 | 79.7% | -0.5 pp | -0.8 pp | |
| LTM Mar 2026 | 77.0% | +9.7 pp | +33.1 pp | |
| LTM Mar 2026 | 73.1% | +0.3 pp | -1.1 pp | |
| LTM Mar 2026 | 67.8% | +0.6 pp | +2.7 pp | |
| LTM Mar 2026 | 65.5% | -2.3 pp | +4.5 pp | |
| LTM Mar 2026 | 48.3% | -1.2 pp | +12.0 pp | |
| LTM Mar 2026 | 14.8% | +0.1 pp | -5.4 pp | |
| Peer median (excluding KIDS) | 67.8% | +0.1 pp | +4.5 pp | |
Competitors are the stored peer set for KIDS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 98.05M | 122.29M | 148.73M | 204.73M | 236.35M |
| Cost of Revenue | 24.65M | 31.63M | 37.48M | 56.13M | 63.69M |
| Gross Profit | 73.4M | 90.66M | 111.25M | 148.6M | 172.66M |
| Gross Margin | 74.9% | 74.1% | 74.8% | 72.6% | 73.1% |
| Research & Development | 5.54M | 8.45M | 10.9M | 11.03M | 9.1M |
| Selling, General & Admin | 85.73M | 104M | 126.12M | 167.09M | 192.56M |
| Operating Expenses | 91.43M | 116.06M | 138M | 178.12M | 201.66M |
| Depreciation & Amortization | 10.68M | 13.1M | 17.39M | 19.08M | 21.25M |
| EBITDA | (7.19M) | (8.69M) | (8.38M) | (20.23M) | (11.94M) |
| EBITDA Margin | -7.3% | -7.1% | -5.6% | -9.9% | -5.1% |
| Operating Income | (18.02M) | (25.4M) | (26.75M) | (29.52M) | (29M) |
| Operating Margin | -18.4% | -20.8% | -18.0% | -14.4% | -12.3% |
| Interest Income | 0 | 0 | 198K | 0 | 0 |
| Interest Expense | 2.25M | 2.42M | 0 | 2.62M | 6M |
| Other Income / Expenses | 636K | 21.71M | 5.44M | (12.41M) | (10.19M) |
| Income Before Tax | (17.39M) | (3.69M) | (21.31M) | (41.93M) | (39.19M) |
| Pre-Tax Margin | -17.7% | -3.0% | -14.3% | -20.5% | -16.6% |
| Income Tax Expense | (1.13M) | (4.95M) | (338K) | (4.11M) | 460K |
| Net Income | (16.26M) | 1.26M | (20.97M) | (37.82M) | (39.65M) |
| Net Margin | -16.6% | 1.0% | -14.1% | -18.5% | -16.8% |
| EPS (Basic) | (0.84) | 0.06 | (0.92) | (1.64) | (1.69) |
| EPS (Diluted) | (0.84) | 0.06 | (0.92) | (1.64) | (1.69) |
| Weighted Avg Shares | 19.27M | 20.7M | 22.68M | 23.08M | 23.46M |
| Weighted Avg Shares (Diluted) | 19.27M | 20.95M | 22.68M | 23.08M | 23.46M |
OrthoPediatrics Corp.
NASDAQ:KIDS
Intrinsic Alpha fair value
Locked
Current Price
$31.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.